BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11320667)

  • 1. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
    Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.
    Boivin AJ; Gourdeau H; Momparler RL
    Cancer Invest; 2004; 22(1):25-9. PubMed ID: 15069761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
    Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
    Adis International Ltd
    Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Investig Drugs; 2007 Apr; 16(4):547-57. PubMed ID: 17371201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
    Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
    Weitman S; Marty J; Jolivet J; Locas C; Von Hoff DD
    Clin Cancer Res; 2000 Apr; 6(4):1574-8. PubMed ID: 10778991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troxacitabine (Shire Pharmaceuticals).
    Ecker G
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1533-8. PubMed ID: 12431032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troxacitabine in acute leukemia.
    Swords R; Giles F
    Hematology; 2007 Jun; 12(3):219-27. PubMed ID: 17558697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
    Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troxacitabine in leukemia.
    Swords R; Apostolidou E; Giles F
    Hematology; 2006 Oct; 11(5):321-9. PubMed ID: 17607581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troxacitabine-based therapy of refractory leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):261-6. PubMed ID: 12113049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Troxacitabine].
    Gourdeau H; Jolivet J
    Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.